The China Securities Regulatory Commission approved the A-Share IPO registration application of HitGen Inc. on March 17, 2020, and JunHe acted as the issuer’s legal counsel. HitGen was successfully listed on the STAR Market of Shanghai Stock Exchange (SSE) on April 16, 2020 with its stock code being 688222.

On March 31, 2020, Grifols, S.A., a company listed on the NASDAQ and Bolsa de Madrid , acquired 26.2% of the equities of Shanghai RAAS Blood Products Co., Ltd., an A-share listed company, and the corresponding shares are listed on the Shenzhen Stock Exchange, completing the final closing of Grifols’ strategic investment in Shanghai RAAS by way of cross-border equity swaps.